{"id":"comparator-placebo-losartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL435","moleculeType":"Small molecule","molecularWeight":"297.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Angiotensin II receptor blockers selectively antagonize AT1 receptors on vascular smooth muscle and adrenal tissue, preventing the vasoconstrictive and sodium-retaining effects of angiotensin II. This results in vasodilation and reduced blood volume, leading to decreased blood pressure. ARBs are commonly compared to other antihypertensive classes like thiazide diuretics (hydrochlorothiazide) and ACE inhibitors in clinical trials.","oneSentence":"This drug is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:12.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: placebo, losartan, hydrochlorothiazide","genericName":"Comparator: placebo, losartan, hydrochlorothiazide","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release. Used for Hypertension, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}